LCTX vs TER · rev $9.5M vs P/E 76, rev $2.82B
Lineage Cell Therapeutics Inc (LCTX) versus Teradyne Inc (TER) — a side-by-side from cached financials, not a winner call.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Teradyne Inc (TER) is a semiconductor equipment & materials company listed on NASDAQ.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
Latest reported TER revenue for 2024-12-31 was $2.82B. Net income was $542.4M. Revenue was up 5.4% from 2023-12-31 to 2024-12-31. TER currently screens at market cap $63.96B and trailing P/E 75.7.
LCTX currently screens at market cap $213.6M. TER currently screens at market cap $63.96B and trailing P/E 75.7.
Not investment advice. Open the LCTX and TER stock pages for the full models.
Not investment advice.